Meningeal involvement in bence jones multiple myeloma

Oda, Kazuhiro; Egawa, Hiromi; Okuhara, Toshio; Sakai, Akira; Hyohdou, Hideo; Tanaka, Hideo; Kuramoto, Atsushi

doi:10.1002/1097-0142(19910401)67:7<1900::aid-cncr2820670714>3.0.co;2-a

Cited by 25 publications

(10 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found 37 case reports, describing isolated CNS MM cases, and two reports of series of 18 and 54 patients respectively (3, 4). The data of a total of 109 patients were reviewed (3–77).…”

Section: Resultsmentioning

confidence: 99%

Central nervous system myelomatosis: review of the literature

Nieuwenhuizen

Biesma

2007

European J of Haematology

117

179

View full text Add to dashboard Cite

Involvement of the central nervous system (CNS) in multiple myeloma (MM) is very uncommon; it has been observed in approximately 1% of the MM patients. This review summarizes the clinical and laboratory characteristics and treatment modalities of 109 patients with CNS myelomatosis (CNS MM) reported in the literature. CNS MM has a wide spectrum of neurological symptoms and signs. No guidelines for therapy of CNS MM are available, which has resulted in a large variation in the treatment schedules. Treatment options include intrathecal chemotherapy (IT), systemic chemotherapy (SC), cranial irradiation (CI) or a combination. The prognosis of CNS MM remains poor, with an overall median survival from the time of diagnosis to death of 2.0 months (range 0.1–25 months). Patients who were treated with CI had a significantly (P = 0.004) longer survival when compared with patients without CI.

show abstract

Section: Resultsmentioning

confidence: 99%

Central nervous system myelomatosis: review of the literature

Nieuwenhuizen

Biesma

2007

European J of Haematology

117

179

View full text Add to dashboard Cite

show abstract

“…In 45 cases there were sufficient clinical data available to allow classification according to the staging system made by Durie and Salmon [49]; 5 cases (11%) had stage I disease, 11 (25%) stage II, and 29 (64%) stage III. MeM has earlier been correlated to high labeling index [50] and to PCL or circulating plasma cells [1,4,6,9,13,14,17,[25][26][27][28]. PCL have been reported to occur with a frequency of 1-5% of patients with MM, depending on the criteria used [17,51].…”

Section: Discussionmentioning

confidence: 99%

Cerebral and meningeal multiple myeloma after autologous stem cell transplantation. A case report and review of the literature

Petersen

Wagner²,

Gimsing

1999

Am. J. Hematol.

View full text Add to dashboard Cite

Meningeal involvement of multiple myeloma is a very rare complication. Defining men-ingeal myelomatosis (MeM) as the presence of plasma cells in the cerebrospinal fluid in a patient with multiple myeloma, we have found 53 previously reported cases in the literature, where the diagnosis MeM has been made while the patient was alive. Using Kaplan Meier statistics we have found the median survival, from the time of diagnosis of MeM, to be 1.5 months. We report a case with MeM and possible cerebral myeloma shortly after autologous stem cell transplantation, and compare it with earlier published cases.

show abstract

“…[2][3][4][5][6][7][8] Often, transient neurological improvement is seen, but progression and death inevitably follow shortly after.…”

mentioning

confidence: 99%